A pharmacokinetic model for radioimmunotherapy delivered through cerebrospinal fluid for the treatment of leptomeningeal metastases

Journal of Nuclear Medicine

Volumn 50, Issue 8, 2009, Pages 1324-1331

  Lv, Yonggang ^a   Cheung, Nai Kong V ^b   Fu, Bingmei M ^a  

^a City College of New York   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

131I 3F8; Cerebrospinal fluid; Intraventricular administration; Kinetic model; Radioimmunotherapy

Indexed keywords

INTRA OMMAYA; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3F8; MONOCLONAL ANTIBODY 3F8 I 131; UNCLASSIFIED DRUG;

ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MENINGEAL METASTASIS; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

ANTIBODIES, MONOCLONAL; CEREBROSPINAL FLUID; COMPUTER SIMULATION; HUMANS; MENINGEAL NEOPLASMS; MODELS, BIOLOGICAL; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; THERAPY, COMPUTER-ASSISTED;

EID: 68249160655     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.060798     Document Type: Article

References (38)

1. Bruno MK, Raizer J. Leptomeningeal metastases from solid tumors (meningeal carcinomatosis). Cancer Treat Res. 2005;125:31-52.
2. Gleissner B, Chamberlain MC. Neoplastic meningitis. Lancet Neurol. 2006; 5:443-452.
3. Grossman SA, Spence A. NCCN clinical practice guidelines for carcinomatous/ lymphotous meningitis. Oncology. 1999;13:144-152.
4. Balm M, Hammack J. Leptomeningeal carcinomatosis: presenting features and prognostic factors. Arch Neurol. 1996;53:626-632.
5. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982;49:759-772.
6. Chamberlain MC. Neoplastic meningitis. J Clin Oncol. 2005;23:3605-3613.
7. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol. 1995;38: 51-57.
8. Smith DB, Howell A, Harris M, Bramwell VH, Sellwood RA. Carcinomatous meningitis associated with infiltrating lobular carcinoma of the breast. Eur J Surg Oncol. 1985;11:33-36.
9. Posner JB. Neurologic Complications of Cancer. Comtemporary Neurology Series, Vol 45. Philadelphia, PA: F.A. Davis Company; 1995.
10. Kramer K, Kushner B, Heller G, Cheung NK. Neuroblastoma metastatic to the central nervous system: the Memorial Sloan-Kettering Cancer Center Experience and a literature review. Cancer. 2001;91:1510-1519.
11. Kramer K, Humm JL, Souweidane MM, et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol. 2007;25:5465-5470.
12. Guyton AC, Hall JE. Textbook of Medical Physiology. 10th ed. Philadelphia, PA: Saunders; 2000.
13. Smith DE, Johanson CE, Keep RF. Peptide and peptide analog transport systems at the blood-CSF barrier. Adv Drug Deliv Rev. 2004;56:1765-1791.
14. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537-1540.
15. 225Ac-HuM195, in nonhuman primates. J Nucl Med. 2004;45:129-137.
16. Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med. 1986;27:1490-1497.
17. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res. 1989;37:77-104.
18. 111In-labeled monoclonal antibody in humans. Cancer Res. 1987;47:3328-3336.
19. Thierens HM, Monsieurs MA, Brans B, Van Driessche T, Christiaens I, Dierckx RA. Dosimetry from organ to cellular dimensions. Comput Med Imaging Graph. 2001;25:187-193.
20. Moseley RP, Davies AG, Richardson RB, et al. Intrathecal administration of 131-I-radiolabelled MoAb as a treatment for neoplastic meningitis. Br J Cancer. 1990;62:637-642.
21. Kemshead JT, Papanastassiou V, Coakham HB, Pizer BL. Monoclonal antibodies in the treatment of central nervous system malignancies. Eur J Cancer. 1992; 28:511-513.
22. 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res. 1996;2:963-972.
23. 90Y: a phase I study. Clin Cancer Res. 1999;5:3275s-3280s.
24. Bigner DD, Brown MT, Friedman AH, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol. 1998;16:2202-2212.
25. 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro-Oncol. 2008;10:182-189.
26. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006;24:823-834.
27. Blasberg RG, Patlak CS, Shapiro WR. Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. Cancer Treat Rep. 1977;61:633-641.
28. Fenstermacher JD, Blasberg RG, Patlak CS. Methods for quantifying the transport of drugs across brain barrier systems. Pharmacol Ther. 1981;14:217-248.
29. Yeh SD, Larson SM, Burch L, et al. Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities. J Nucl Med. 1991;32:769-776.
30. Silverberg GD, Heit G, Huhn S, et al. The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer's type. Neurology. 2001;57:1763-1766.
31. Barta P, Dazzan P. Hemispheric surface area: sex, laterality and age effects. Cereb Cortex. 2003;13:364-370.
32. Errera M, Forssberg A. Mechanisms in Radiobiology. 1st ed. New York, NY: Academic Press; 1960.
33. off) [abstract]. J Clin Oncol. 2007;25(June 20 suppl):13507.
34. Cheung NK, Modak S, Lin Y, et al. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. J Nucl Med. 2004;45:867-877.
35. 22Na transfer across the blood-brain and blood-CSF barriers. J Neurochem. 1989;52:1058-1063.
36. Johanson CE. Differential effects of acetazolamide, benzolamide and systemic acidosis on hydrogen and bicarbonate gradients across the apical and basolateral membranes of the choroid plexus. J Pharmacol Exp Ther. 1984;231:〉502-511.
37. Knuckey NW, Preston J, Palm D, Epstein MH, Johanson C. Hydrocephalus decreases chloride efflux from the choroid plexus epithelium. Brain Res. 1993;618:313-317.
38. Hakvoort A, Johanson CE. Growth factor modulation of CSF formation by isolated choroid plexus: FGF-2 vs. TGF-beta1. Eur J Pediatr Surg. 2000;10:44-46.